The lack of association between MADRS score change and VEGF level change suggests that effective treatment of anhedonia as a core symptom of antidepressant resistant depression can be dependent on the capacity of the VEGF pathway and stimulation of the DLPFC in patients with MDD. Here, VEGFA is linked to depressive symptom measurement.